[1]Scott;Kennedy;Kemp;Telang;Matthews[JournalofPharmaceuticalSciences,1983,vol.72,#2,p.183-186]
[1]Lettersindrugdesignanddiscovery,2020,vol.17,p.731-744
1010-26-0
10233-13-3
123-29-5
123-95-5
124-06-1
1190-63-2
612042-78-1 | 3-[[(2,6-DICHLOROPHENYL)SULFONYL]AMINO]PROPANOIC ACID | AA00ECLD | MFCD03619052
615-99-6 | DIALLYL OXALATE | AA00ECQU | MFCD00053698
5665-94-1 | LABOTEST-BB LT00233115 | AA00ECYI | MFCD00020137
6453-67-4 | Pyropheophorbide a methyl ester | AA00ED77 | MFCD00057989
63353-12-8 | TRINEOPHYLTIN HYDRIDE | AA00EDCI | MFCD08275540
58010-91-6 | 4-Methyl-2-p-tolylazo-phenylamine | AA00EDOT | MFCD00025370
588714-50-5 | 5-Isopropyl-3-(morpholin-4-ylcarbonyl)thien-2-ylamine | AA00EDT7 | MFCD03945259
56302-41-1 | 4-(Pyrrolidinocarbonyl)aniline | AA00EDWS | MFCD02046794
6154-30-9 | 2,5-Dibromo-4-nitro-1H-imidazole | AA00EE17 | MFCD11877989
634884-72-3 | 3-(3,5-Dimethyl-1h-pyrazol-4-yl)propanohydrazide | AA00EE4N | MFCD01134800